RxDoctor Payments Data

Timothy Ball, MD

Clinical Cardiac Electrophysiology · Waco, TXNPI 1225342397

Payments from drug & device makers

$58,357in general payments, 2019–2025

Across 811 payments — averaging $71.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$32K
  • Abbott$14K
  • Biosense Webster, Inc.$5K
  • Medtronic$3K
  • Medical Device Business Services, Inc.$2K
  • Atricure, Inc.$218
  • plus $2K from 21 others

What the payments were for

  • Consulting fees$2,4444%
  • Speaking & faculty fees$12,50021%
  • Travel & lodging$19,47033%
  • Food & beverage$23,94441%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,357 in reported general payments places this provider in the 60th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$841,604
Medicare patients
2,493
Services billed
9,865

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban287$216,794
XareltoRivaroxaban81$67,101
MultaqDronedarone Hcl73$63,335
FarxigaDapagliflozin Propanediol24$13,832
Flecainide Acetate263$10,317
Metoprolol Succinate348$4,064
ClopidogrelClopidogrel Bisulfate208$3,213
Amiodarone Hcl130$2,558
SotalolSotalol Hcl47$894
Diltiazem 24hr ErDiltiazem Hcl33$841
Diltiazem 24hr Er (Cd)Diltiazem Hcl30$794
Carvedilol104$608
Diltiazem Hcl11$412
Digoxin23$347
Metoprolol Tartrate60$335

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$78$67,10181 claims
Sanofi-aventis U.S. LLCMultaq$22$63,33573 claims
AstraZenecaFarxiga$83$13,83224 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →